Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Mim8 prophylaxis in children with hemophilia A with or without factor VIII inhibitors
MOH_2022-06-16_010584Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of denecimig in hemophilia A (2 arms), sponsored by Novo Nordisk. Started Jan 2022; status: active, not recruiting.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2022-06-16_010584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-16_010584.